Latest News

Sarepta Soars 31% As FDA Panel Backs Muscular Dystrophy Therapy

Sarepta Therapeutics soars 31% as FDA committee supports gene therapy for Duchenne muscular dystrophy. Analysts have a “moderate buy” rating on the stock.

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News